Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data.Contemporary clinical trials · 2023Pooled it
- Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.Journal for immunotherapy of cancer · 2021Pooled it
- Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.Bioscience reports · 2020Pooled it
- Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.The Lancet. Oncology · 2023Trial
- Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.Breast cancer research and treatment · 2021Trial
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.NPJ breast cancer · 2026Review
- Is Genetic Testing of HER2-Negative Metastatic Breast Cancer Patients Implemented into Clinical Practice? A Retrospective Analysis.Journal of clinical medicine · 2026Article
- PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge.Experimental & molecular medicine · 2026Review
- Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies.Journal of Zhejiang University. Science. B · 2025Review
- DNA damage response in breast cancer and its significant role in guiding novel precise therapies.Biomarker research · 2024Review
- Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.International journal of molecular sciences · 2024Review
- Clinical efficacy of PARP inhibitors in breast cancer.Breast cancer research and treatment · 2023Review
- A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).Breast cancer research and treatment · 2023Article
- Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.Journal of immunotherapy and precision oncology · 2023Review
- Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.Biologics : targets & therapy · 2023Review
- Targeting nuclear hormone receptors for the prevention of breast cancer.Frontiers in medicine · 2023Review
- Opinion: PARP inhibitors in cancer-what do we still need to know?Open biology · 2022Review
- A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.Cancer chemotherapy and pharmacology · 2022Article
- Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.NPJ breast cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 1 country.
George SomloCity of Hope Comprehensive Cancer Center, Duarte, California. jweitzel@coh.org gsomlo@coh.org.
Paul H FrankelCity of Hope Comprehensive Cancer Center, Duarte, California.
Banu K ArunThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Cynthia X MaWashington University School of Medicine, St. Louis, Missouri.
Agustin A GarciaUniversity of Southern California/Norris Cancer Center, Los Angeles, California.
Tessa CiglerWeill Cornell Medicine, New York, New York.
Leah V CreamMilton S. Hershey Medical Center, Hershey, Pennsylvania.
Harold A HarveyMilton S. Hershey Medical Center, Hershey, Pennsylvania.
Joseph A SparanoMontefiore Medical Center, Moses & Weuker Divisions, Department of Oncology, Bronx, New York.
Rita NandaThe University of Chicago, Chicago, Illinois.
Helen K ChewUniversity of California, Davis Cancer Center, Sacramento, California.
Timothy J MoynihanMayo Clinic Cancer Center, Rochester, Minnesota.
Linda T VahdatWeill Cornell Medicine, New York, New York.
Matthew P GoetzMayo Clinic Cancer Center, Rochester, Minnesota.
Jan H BeumerUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Arti HurriaCity of Hope Comprehensive Cancer Center, Duarte, California.
Joanne MortimerCity of Hope Comprehensive Cancer Center, Duarte, California.
Richard PiekarzInvestigational Drug Branch, Cancer Therapy Evaluation Program, DCTD, NCI, Bethesda, Maryland.
Sharon SandCity of Hope Comprehensive Cancer Center, Duarte, California.
Josef HerzogCity of Hope Comprehensive Cancer Center, Duarte, California.
Lily R Van TongerenCity of Hope Comprehensive Cancer Center, Duarte, California.
Katherine V Ferry-GalowApplied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratories, Frederick, Maryland.
Alice P ChenInvestigational Drug Branch, Cancer Therapy Evaluation Program, DCTD, NCI, Bethesda, Maryland.
Christopher RuelCity of Hope Comprehensive Cancer Center, Duarte, California.
Edward M NewmanCity of Hope Comprehensive Cancer Center, Duarte, California.
David R GandaraUniversity of California, Davis Cancer Center, Sacramento, California.
Jeffrey N WeitzelCity of Hope Comprehensive Cancer Center, Duarte, California. jweitzel@coh.org gsomlo@coh.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Southern California · USWashington University in St. Louis · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MTexas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos · 2014 to 2026
$20.4MPhase I Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov · 2014 to 2026
$19.8MNCI ET-CTN with Phase i Emphasis at UPCIUM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani · 2014 to 2026
$9.1MNovel targeted therapies for BRCA-associated cancerR21CA137684 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WEITZEL, JEFFREY N · 2010 to 2011
$679kREGULATION OF RADIATION-INDUCED APOPTOTIC CELL DEATHR29CA062209 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI STORY, MICHAEL D · 1994 to 1998
–CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS N01 CM062209NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA047904NCI NIH HHS R21 CA137684NCI NIH HHS UM1 CA186688NCI NIH HHS UM1 CA186690NCI NIH HHS UM1 CA186717
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCaliforniaCarboplatinCombined Modality TherapyDisease-Free SurvivalFemaleGerm-Line MutationHumansMiddle AgedNeoplasm MetastasisBenzimidazolesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCarboplatinPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitorsveliparib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.